Eva de Lago

2.4k total citations
47 papers, 1.8k citations indexed

About

Eva de Lago is a scholar working on Pharmacology, Neurology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Eva de Lago has authored 47 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pharmacology, 22 papers in Neurology and 18 papers in Cellular and Molecular Neuroscience. Recurrent topics in Eva de Lago's work include Cannabis and Cannabinoid Research (36 papers), Amyotrophic Lateral Sclerosis Research (19 papers) and Parkinson's Disease Mechanisms and Treatments (16 papers). Eva de Lago is often cited by papers focused on Cannabis and Cannabinoid Research (36 papers), Amyotrophic Lateral Sclerosis Research (19 papers) and Parkinson's Disease Mechanisms and Treatments (16 papers). Eva de Lago collaborates with scholars based in Spain, United Kingdom and Italy. Eva de Lago's co-authors include Javier Fernández‐Ruíz, J.A. Ramos, Francisco Espejo‐Porras, Moisés Garcı́a-Arencibia, Miguel Moreno‐Martet, Vincenzo Di Marzo, Raphael Mechoulam, Silvia Ortega‐Gutiérrez, Sara González and Ana Cabranes and has published in prestigious journals such as Scientific Reports, Brain Research and International Journal of Molecular Sciences.

In The Last Decade

Eva de Lago

45 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eva de Lago Spain	27	1.4k	907	343	263	248	47	1.8k
Concepción García Spain	24	1.0k 0.7×	757 0.8×	284 0.8×	228 0.9×	371 1.5×	59	1.7k
Anke Witting Germany	22	1.3k 0.9×	928 1.0×	481 1.4×	340 1.3×	565 2.3×	25	2.5k
Allyn Franklin United States	11	849 0.6×	571 0.6×	115 0.3×	263 1.0×	188 0.8×	11	1.3k
Ana Juknat Israel	21	1.3k 0.9×	467 0.5×	54 0.2×	236 0.9×	298 1.2×	23	1.7k
Sharon Goodenough Germany	13	886 0.6×	865 1.0×	59 0.2×	287 1.1×	324 1.3×	16	1.6k
Sophie Parmentier‐Batteur United States	14	573 0.4×	596 0.7×	81 0.2×	240 0.9×	388 1.6×	16	1.3k
Asami Tanimura Japan	18	619 0.4×	901 1.0×	181 0.5×	425 1.6×	317 1.3×	36	1.5k
Silvia Marinelli Italy	20	525 0.4×	1.0k 1.1×	92 0.3×	330 1.3×	470 1.9×	33	1.8k
Susana Mato Spain	23	1.2k 0.9×	1.2k 1.3×	43 0.1×	512 1.9×	469 1.9×	39	2.1k
Carmen Mazzola Italy	14	456 0.3×	608 0.7×	78 0.2×	151 0.6×	315 1.3×	19	1.0k

Countries citing papers authored by Eva de Lago

Since Specialization

Citations

This map shows the geographic impact of Eva de Lago's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva de Lago with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva de Lago more than expected).

Fields of papers citing papers by Eva de Lago

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva de Lago. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva de Lago. The network helps show where Eva de Lago may publish in the future.

Co-authorship network of co-authors of Eva de Lago

This figure shows the co-authorship network connecting the top 25 collaborators of Eva de Lago. A scholar is included among the top collaborators of Eva de Lago based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva de Lago. Eva de Lago is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fernández‐Ruíz, Javier, Onintza Sagredo, María Gómez‐Ruíz, & Eva de Lago. (2025). Ageing, Neurodegeneration and the Endocannabinoid System. Current topics in behavioral neurosciences. 76. 209–248.

Rodríguez‐Cueto, Carmen, et al.. (2024). Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia. Antioxidants. 13(9). 1072–1072. 1 indexed citations

Rodríguez‐Cueto, Carmen, Fabiana Piscitelli, Anna Lauritano, et al.. (2023). Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice. Journal of Neuroinflammation. 20(1). 108–108. 7 indexed citations

Maestro, Inés, Laura Rodríguez de la Ballina, Silvia Corrochano, et al.. (2022). Discovery of Mitophagy Inhibitors with Therapeutic Potential in Different Familial Amyotrophic Lateral Sclerosis Mutations. International Journal of Molecular Sciences. 23(20). 12676–12676. 9 indexed citations

Nozal, Vanesa, Loreto Martínez‐González, Paula Santana, et al.. (2022). TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy. Journal of Medicinal Chemistry. 65(2). 1585–1607. 28 indexed citations

García, Concepción, Francisco Ruíz-Pino, Juan D. Unciti‐Broceta, et al.. (2021). Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis. Molecules. 26(24). 7643–7643. 16 indexed citations

Rojas, Pilar, Ana I. Ramı́rez, José A. Fernández‐Albarral, et al.. (2021). Retinal Ganglion Cell Loss and Microglial Activation in a SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences. 22(4). 1663–1663. 11 indexed citations

Martínez‐González, Loreto, et al.. (2021). Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3β as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences. 22(16). 8975–8975. 45 indexed citations

Martínez‐González, Loreto, Nicole F. Liachko, Concepción Pérez, et al.. (2020). Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis. European Journal of Medicinal Chemistry. 210. 112968–112968. 37 indexed citations

10.

Martínez‐González, Loreto, Carmen Rodríguez‐Cueto, Fernando Benito Bartolomé, et al.. (2020). Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment. Scientific Reports. 10(1). 4449–4449. 42 indexed citations

11.

Moreno‐Martet, Miguel, Ana Feliú, Francisco Espejo‐Porras, et al.. (2015). The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ-tetrahydrocannabinol acting through CB1 receptors. Multiple Sclerosis and Related Disorders. 4(6). 505–511. 29 indexed citations

12.

Moreno‐Martet, Miguel, Francisco Espejo‐Porras, Javier Fernández‐Ruíz, & Eva de Lago. (2014). Changes in Endocannabinoid Receptors and Enzymes in the Spinal Cord of SOD1^G93A Transgenic Mice and Evaluation of a Sativex^®‐like Combination of Phytocannabinoids: Interest for Future Therapies in Amyotrophic Lateral Sclerosis. CNS Neuroscience & Therapeutics. 20(9). 809–815. 58 indexed citations

13.

Moreno‐Martet, Miguel, Leyre Mestre, Frida Loría, et al.. (2011). Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases. Neuroscience Letters. 508(2). 67–72. 12 indexed citations

14.

Sagar, Devi Rani, Maulik D. Jhaveri, Denise Richardson, et al.. (2010). Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain. European Journal of Neuroscience. 31(8). 1414–1422. 27 indexed citations

15.

Sagredo, Onintza, et al.. (2007). Cannabinoids and Neuroprotection in Basal Ganglia Disorders. Molecular Neurobiology. 36(1). 82–91. 74 indexed citations

16.

Lago, Eva de, et al.. (2006). Acyl‐based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. Journal of Neurochemistry. 99(2). 677–688. 24 indexed citations

17.

Lago, Eva de, Silvia Ortega‐Gutiérrez, J.A. Ramos, María L. López-Rodrı́guez, & Javier Fernández‐Ruíz. (2006). Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions. Life Sciences. 80(10). 979–988. 9 indexed citations

18.

Lago, Eva de, Javier Fernández‐Ruíz, Silvia Ortega‐Gutiérrez, et al.. (2005). UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. European Neuropsychopharmacology. 16(1). 7–18. 60 indexed citations

19.

Lago, Eva de, Rosario de Miguel, Isabel Lastres‐Becker, J.A. Ramos, & Javier Fernández‐Ruíz. (2004). Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Research. 1007(1-2). 152–159. 78 indexed citations

20.

Lago, Eva de, Alessia Ligresti, Giorgio Ortar, et al.. (2003). In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. European Journal of Pharmacology. 484(2-3). 249–257. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact